Journal
PHARMACOLOGICAL REPORTS
Volume 67, Issue 3, Pages 569-580Publisher
SPRINGER HEIDELBERG
DOI: 10.1016/j.pharep.2014.12.015
Keywords
Oxidative biomarker; Antioxidant defense molecule; Non-enzymatic and enzymatic antioxidant; Clinical study; Animal study
Categories
Funding
- National Science Centre (Krakow, Poland) [UMO-2012/05/B/NZ7/02589, UMO-2011/01/B/NZ4/00708]
- Jagiellonian University Medical College [K/ZDS/004127]
Ask authors/readers for more resources
The pathophysiology of psychiatric diseases, including depression, anxiety, schizophrenia and autism, is far from being fully elucidated. In recent years, a potential role of the oxidative stress has been highlighted in the pathogenesis of neuropsychiatric disorders. A body of clinical and preclinical evidence indicates that psychiatric diseases are characterized by higher levels of oxidative biomarkers and with lower levels of antioxidant defense biomarkers in the brain and peripheral tissues. In this article, we review current knowledge on the role of the oxidative stress in psychiatric diseases, based on clinical trials and animal studies, in addition, we analyze the effects of drug-induced modulation of oxidative balance and explore pharmacotherapeutic strategies for oxidative stress reduction. (C) 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available